Appearing on behalf of the International Gene Synthesis Consortium (IGSC) member companies, Integrated DNA Technologies (IDT), a leader in custom nucleic acid synthesis, yesterday spoke at the Presidential Commission for the Study of Bioethical Issues, in Philadelphia, PA, USA.
The IGSC represents approximately 80% of the worldwide gene synthesis capacity and has been working with the US and other governments to establish standards and practices to prevent the misuse of synthetic genes. Having taken a prominent role in the recent public policy discussion of the biosafety and biosecurity concerns relating to gene synthesis technology, IDT has helped to lead the development of the IGSC’s Harmonized Screening Protocol. The Commission invited IDT to its second public meeting to describe those efforts.